Our Yaz health problem lawsuit attorneys are always trying to provide readers with more information about the recent lawsuits surrounding the birth control pill Yaz, along with its generics, Yasmin and Ocella.
Read the following excerpt from the article, “The Mass Tort of the Year: Yaz, Yasmin, and Ocella” from American Trail Lawyer:
“Bayer heavily invested in marketing the pills, hiking its advertising budget for Yaz 253% from 2006 to 2007, for a total budget of $75.8 million. Their only product receiving more advertising dollars was Aleve. The campaign has been highly successful, with the Bayer0manufactured pills being the best-selling oral contraceptives in this country. The company earned about $1.8 billion worldwide in 2008, with over $600 million of those sales in the United States. In October 2009, Bayer announced that sales for the pills rose 4.6% over the previous quarter.
While the advertising connected with consumers, the FDA found that the marketing claims had not been borne out by research. In the last six years, the FDA has warned manufacturers about the language of the advertisements in three letters – in 2003, 2008, and January 2009 – noting that the advertising for the pills overstated the effectiveness and minimized dangers. The FDA specifically expressed concern that the risks were being minimized, by failing to communicate risk adequately, and that marketing suggested the pills were an appropriate treatment for PMS and could result in the acne-free skin. In fact, they have only been found effective in treating a severe form of PMS called premenstrual dysphoric disorder (PMDD) and for the treatment of moderate acne.”